Explore more publications!
Latin America Health Times
Got News to Share?

Latin America Health Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Latin America Health Times.

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

Press releases published on December 8, 2025

Flower Turbines Announces Grant of Patent on Data Center Energy and Air Systems
December 8, 2025

Flower Turbines Announces Grant of Patent on Data Center Energy and Air Systems

Indeterminate EIN Presswire
Amyotrophic Lateral Sclerosis Market Set to Grow at an Impressive CAGR of 4.01% Through 2035 | 1.295 (USD Billion)
December 8, 2025

Amyotrophic Lateral Sclerosis Market Set to Grow at an Impressive CAGR of 4.01% Through 2035 | 1.295 (USD Billion)

Indeterminate EIN Presswire
Aesthetics Market Expected to Achieve a Strong 6.5% CAGR, to Reach USD 300 Billion by 2035
December 8, 2025

Aesthetics Market Expected to Achieve a Strong 6.5% CAGR, to Reach USD 300 Billion by 2035

Indeterminate EIN Presswire
AskForHelpToday.ca Launches in New Brunswick, Improving Access to Mental Health Care
December 8, 2025

AskForHelpToday.ca Launches in New Brunswick, Improving Access to Mental Health Care

Indeterminate GlobeNewswire
AskForHelpToday.ca est lancé au Nouveau-Brunswick, améliorant l’accès aux soins en santé mentale
December 8, 2025

AskForHelpToday.ca est lancé au Nouveau-Brunswick, améliorant l’accès aux soins en santé mentale

Indeterminate GlobeNewswire
Geneva College of Longevity Science and DrVibe.ai Launch the GCLS AI Academy for Longevity Sciences
December 8, 2025

Geneva College of Longevity Science and DrVibe.ai Launch the GCLS AI Academy for Longevity Sciences

Indeterminate GlobeNewswire
Pan Cancer T Secures EUR 10 Million to Advance First-in-Human Trial of Novel TCR-T Cell Therapy for Triple-Negative Breast Cancer
December 8, 2025

Pan Cancer T Secures EUR 10 Million to Advance First-in-Human Trial of Novel TCR-T Cell Therapy for Triple-Negative Breast Cancer

Indeterminate GlobeNewswire
Amphista Therapeutics presents new preclinical data showing the potential of its BRD9 Targeted Glue™, AMX-883, to transform the treatment paradigm for acute myeloid leukaemia
December 8, 2025

Amphista Therapeutics presents new preclinical data showing the potential of its BRD9 Targeted Glue™, AMX-883, to transform the treatment paradigm for acute myeloid leukaemia

Indeterminate GlobeNewswire
FIRST PATIENT DOSED IN CITRYLL’S PHASE IIA HIDRADENITIS SUPPURATIVA TRIAL
December 8, 2025

FIRST PATIENT DOSED IN CITRYLL’S PHASE IIA HIDRADENITIS SUPPURATIVA TRIAL

Indeterminate GlobeNewswire
EpiEndo Pharmaceutical's ERJ Open Research article reports first clinical trial of glasmacinal (EP395) in COPD patients
December 8, 2025

EpiEndo Pharmaceutical's ERJ Open Research article reports first clinical trial of glasmacinal (EP395) in COPD patients

Indeterminate GlobeNewswire
Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025
December 8, 2025

Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025

Indeterminate GlobeNewswire
Galapagos presenteerde nieuwe ATALANTA-1 celtherapiedata in MCL op ASH 2025
December 8, 2025

Galapagos presenteerde nieuwe ATALANTA-1 celtherapiedata in MCL op ASH 2025

Indeterminate GlobeNewswire
OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development
December 8, 2025

OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development

Indeterminate GlobeNewswire
OSE Immunotherapeutics annonce un amendement stratégique au partenariat avec AbbVie sur le développement d’ABBV-230
December 8, 2025

OSE Immunotherapeutics annonce un amendement stratégique au partenariat avec AbbVie sur le développement d’ABBV-230

Indeterminate GlobeNewswire
ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL
December 8, 2025

ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL

Indeterminate GlobeNewswire
ASH 2025 : Cellectis présente son plan de développement pour renforcer les taux de réponse élevés obtenus avec éti-cel dans le LNH en rechute ou réfractaire
December 8, 2025

ASH 2025 : Cellectis présente son plan de développement pour renforcer les taux de réponse élevés obtenus avec éti-cel dans le LNH en rechute ou réfractaire

Indeterminate GlobeNewswire
Miltenyi Biomedicine stellt die Primäranalyse der zulassungsrelevanten DALY-2-EU-Studie zur Zweitlinientherapie des rezidivierten/refraktären großzelligen B-Zell-Lymphoms auf der 67. Jahrestagung der American Society of Hematology (ASH) vor
December 8, 2025

Miltenyi Biomedicine stellt die Primäranalyse der zulassungsrelevanten DALY-2-EU-Studie zur Zweitlinientherapie des rezidivierten/refraktären großzelligen B-Zell-Lymphoms auf der 67. Jahrestagung der American Society of Hematology (ASH) vor

Indeterminate GlobeNewswire
Miltenyi Biomedicine presenta el análisis primario del ensayo pivotal DALY 2-EU para el linfoma de células B grandes en recaída/refractario de segunda línea en la 67.ª Reunión Anual de la American Society of Hematology (ASH)
December 8, 2025

Miltenyi Biomedicine presenta el análisis primario del ensayo pivotal DALY 2-EU para el linfoma de células B grandes en recaída/refractario de segunda línea en la 67.ª Reunión Anual de la American Society of Hematology (ASH)

Indeterminate GlobeNewswire
À l’occasion de la 67e réunion annuelle de l’American Society of Hematology (ASH), Miltenyi Biomedicine présente l’analyse primaire de l’essai pivot DALY 2-EU pour le traitement de seconde ligne du lymphome à grandes cellules B en rechute ou réfractair…
December 8, 2025

À l’occasion de la 67e réunion annuelle de l’American Society of Hematology (ASH), Miltenyi Biomedicine présente l’analyse primaire de l’essai pivot DALY 2-EU pour le traitement de seconde ligne du lymphome à grandes cellules B en rechute ou réfractair…

Indeterminate GlobeNewswire
Miltenyi Biomedicine מציגה ניתוח ראשוני של ניסוי DALY 2-EU מרכזי לטיפול בהישנות/עמידות לטיפול קו שני של לימפומה של תאי B גדולים בכנס השנתי ה-67 של האגודה האמריקנית להמטולוגיה (ASH…
December 8, 2025

Miltenyi Biomedicine מציגה ניתוח ראשוני של ניסוי DALY 2-EU מרכזי לטיפול בהישנות/עמידות לטיפול קו שני של לימפומה של תאי B גדולים בכנס השנתי ה-67 של האגודה האמריקנית להמטולוגיה (ASH…

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions